- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Diagnostic Testing to Identify PD-L1 Inhibitor Response in Lung Cancer
Naiyer A. Rizvi, MD, director of thoracic oncology and immunotherapeutics at Columbia University Medical Center discusses using PD-L1 expression on a tumor to identify patient response to treatment.
Naiyer A. Rizvi, MD, director of thoracic oncology and immunotherapeutics at Columbia University Medical Center discusses using PD-L1 expression on a tumor and its benefits.
Transcript
We are pre-identifying patients by PD-L1 expression on the tumor; it’s an immunohistochemical assay and it’s fairly easy to do. High levels of PD-L1 expression do tend to correlate with benefit—it’s not a perfect biomarker; there’s both false positives and negatives. It’s not a binary biomarker, like EGFR mutation testing, but it does provide some guide to who is more likely to benefit.
The approval of pembrolizumab first-line treatment, a single agent in lung cancer was based on KEYNOTE-024 where patients who have more than 50% of PD-L1 expression, which is about a third of non-small cell lung cancer and in those patients, they had a superior response rate, progression-free survival, as well as overall survivor with single-agent pembrolizumab versus chemotherapy.
So, based on that data, and really the standard of care, to test for PD-L1 expression if you’re positive at the 50% threshold and treat with single agent pembrolizumab and not chemotherapy.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More
